Views & Analysis
R&D roundup: the ups and downs of CRISPR and Alzheimer’s
While the controversy surrounding Vertex Pharma’s cystic fibrosis drug in the UK grows more intense, the US firm has announced that it is licensing back two gene editing compounds that can
